Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 70

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 70
---
statement, during prosecution. A litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have
conducted our patent prosecution in accordance with the duty of candor and in good faith. The outcome following such a challenge is unpredictable.

Third parties may also raise
similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
re-examination, inter partesreview, post-grant review and equivalent proceedings in foreign jurisdictions (such as opposition
proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product
candidates.

The outcome following legal
assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain
that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a
defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect
our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection
could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.
Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in
a manner that would limit our ability to enforce such claims against the defendant and others. The cost of defending such a challenge,
particularly in a foreign jurisdiction, and any resulting loss of patent protection could have a material adverse impact on one or more
of our product candidates and our business. Any efforts to enforce our intellectual property rights are also likely to be costly and may
divert the efforts of our scientific and management personnel.

Changes to patent law in the United States
and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.

Changes in either the patent
laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability
to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value
of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and
other countries, including the